# RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

> **NCT05979740** · PHASE2 · UNKNOWN · sponsor: **RenJi Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Muscle Invasive Bladder Cancer
- HER2 Expression
- Radiotherapy
- PD-1
- Antibody-drug Conjugates

## Interventions

- **DRUG:** Disitamab Vedotin and Toripalimab

## Key facts

- **NCT ID:** NCT05979740
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2023-12-13
- **Final completion:** 2024-02-13
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05979740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05979740, "RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05979740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*